TABLE 2.
Univariate analysis for progression‐free survival (PFS) among patients with non‐small cell lung cancer (n = 92)
| No. of patients | Median PFS, months (95% CI) | p value | |
|---|---|---|---|
| Age categorization, years | |||
| <75 | 60 | 17.4 (12.5–22.8) | 0.656 |
| ≥75 | 32 | 15.6 (11.8–23.2) | |
| Sex | |||
| Male | 27 | 16.5 (13.5–23.2) | 0.857 |
| Female | 65 | 18.1 (11.9–23.8) | |
| PS | |||
| 0, 1 | 77 | 21.6 (14.7–24.0) | <0.001 |
| 2, 3 | 15 | 8.9 (2.4–15.4) | |
| Disease stage | |||
| III, IV | 75 | 15.6 (11.9–21.8) | 0.610 |
| Postoperative relapse | 17 | 23.8 (13.5–26.6) | |
| Brain metastasis | |||
| Positive | 27 | 12.9 (8.0–18.1) | 0.058 |
| Negative | 65 | 21.5 (14.4–24.4) | |
| Histology | |||
| Adenocarcinoma | 88 | 18.1 (14.4–22.1) | 0.444 |
| Others | 4 | 4.0 (1.5–NE) | |
| EGFR mutation | |||
| 19del | 47 | 21.8 (15.4–26.6) | <0.001 |
| L858R | 43 | 14.7 (9.9–21.6) | |
| Others | 2 | 3.0 (1.0–NE) | |
| Smoking status | |||
| Current or former smoker | 36 | 13.8 (9.0–21.6) | 0.169 |
| Never smoker | 56 | 21.5 (14.7–24.4) | |
| IHC for AXL | |||
| High | 24 | 8.9 (6.1–17.4) | 0.026 |
| Low | 68 | 21.5 (15.4–24.0) | |
| IHC for p53 | |||
| Positive | 49 | 14.7 (10.3–21.6) | 0.144 |
| Negative | 43 | 21.5 (14.4–26.6) | |
| PD‐L1 TPS | |||
| ≥50% | 13 | 6.5 (2.4–14.4) | 0.005 |
| <50% | 51 | 17.4 (12.9–21.8) | |
| Unknown | 28 | 26.1 (14.7–29.1) |
Abbreviations: 19del, exon 19 deletion; CI, confidence interval; IHC, immunohistochemistry; L858R, exon21 L858R point mutation; NE, not evaluable; PD‐L1, programmed death‐ligand 1; PFS, progression‐free survival; PS, performance status; TPS, tumor proportion score.